Erlanger Hospital Opens CIDP Clinical Trial
Adults with the rare neurological condition in Chattanooga can now enroll in a phase three study.
Updated on Oct. 21, 2026 in Alzheimer’s
Live Poll
Would you consider participating in a clinical trial to gain access to an investigational medical treatment?
Erlanger Hospital in Chattanooga has opened enrollment for a phase three clinical trial investigating a new treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). This neurological condition causes muscle weakness and sensory loss, and participation is currently open to eligible local adults.
Why it matters
Clinical research is essential for expanding treatment options for rare diseases, as fewer than 5% of these conditions currently have an FDA-approved therapy. Access to trials provides local patients with potential new care paths while contributing to the scientific understanding of rare neurological disorders.
This phase three clinical trial is currently evaluating the safety and function of an investigational drug in adults diagnosed with CIDP. While the study works to address a significant gap in care, the drug's performance compared to existing standards remains unresolved.
The players
Erlanger Hospital
A Chattanooga-based health system currently serving as a designated site for clinical research into rare neurological conditions.
The details
CIDP is a complex neurological disorder characterized by inflammation that damages the protective coverings of nerves, leading to progressive muscle weakness and sensory loss. The study at Erlanger Hospital evaluates how an investigational therapy functions within the body to potentially mitigate this nerve damage. Researchers are focused on assessing both the safety and clinical impact of the intervention in patients who currently have limited treatment options.
Timeline
• October 2026: Phase three clinical trials are open for enrollment to eligible adults.
Health Landscape
The clinical trial at Erlanger Hospital addresses the substantial medical gap faced by the 30 million Americans living with a rare disease. Because fewer than 5% of these conditions have FDA-approved treatments, such research is a critical driver for evolving standards of care.
Adults in Chattanooga diagnosed with CIDP who are interested in exploring research participation should consult with their physician to determine if they meet the eligibility criteria. Discussing the potential risks and requirements of a phase three trial is an important step in clinical care.
The takeaway
Advancing clinical trials is the primary method for addressing the scarcity of approved treatments for rare diseases like CIDP. If you are managing this condition, speak with your specialist about whether a clinical trial is a suitable option to explore in your care plan.
Further reading
For more information on navigating neurological research, visit the Alzheimer’s section of our site.
More information
To review eligibility requirements, visit the clinical trial enrollment and information page.
Source note: This article includes information reported by News 12 Now.
Live Poll
Would you consider participating in a clinical trial to gain access to an investigational medical treatment?
